Advice
following a full submission:
naldemedine (Rizmoic®) is accepted for use within NHSScotland.
Indication under review: For the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid-induced constipation and either non-cancer or cancer pain.
Medicine details
- Medicine name:
- naldemedine (Rizmoic)
- SMC ID:
- SMC2242
- Indication:
For the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
- Pharmaceutical company
- Shionogi Limited
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2020